# Exosomes Derived from BMSCs Treated with CeONPs Ameliorate Radiation-Induced Jaw Bone Injury via miR-21-5p/STAT3 Axis-Mediated Osteogenesis and ROS Scavenging

**Authors:** Zhiyue Zhang, Heng Li, Chong Huang, Ting Mou, Jiaqi Tian, Zeyang Ge, Lu Zhao, Dandan Wang, Chenlu Li, Taiqiang Dai, Chunlin Zong, Lei Tian

PMC · DOI: 10.3390/pharmaceutics18020216 · 2026-02-09

## TL;DR

Exosomes from bone marrow stem cells treated with cerium oxide nanoparticles help repair radiation-damaged jaw bones by boosting bone formation and reducing oxidative stress.

## Contribution

BMSC-Ce-exos offer a novel therapeutic strategy for radiation-induced jaw bone injury via miR-21-5p/STAT3 signaling and ROS scavenging.

## Key findings

- BMSC-Ce-exos significantly promoted osteogenic differentiation and reduced ROS levels in irradiated BMSCs in vitro.
- In vivo, BMSC-Ce-exos enhanced bone formation and reduced ROS in rats with radiation-induced jaw bone injury.
- miR-21-5p in BMSC-Ce-exos targets STAT3 to promote osteogenesis and reduce ROS in irradiated BMSCs.

## Abstract

Background/Objectives: Radiation-induced jaw bone injury is a severe and refractory complication following radiotherapy, and the key to treatment is promoting osteogenic differentiation and alleviating oxidative stress injury in irradiated BMSCs. Cerium oxide nanoparticles (CeONPs) exhibit considerable research potential in various oxidative stress injury-related diseases due to their excellent reactive oxygen species (ROS) scavenging capacity; however, its biosafety risk makes direct application in disease treatment a matter of controversy. Methods: Recent evidence suggests that treating cells with nanoparticles can regulate the content of exosomes, enhancing the regenerative potential of exosomes. Accordingly, this study was designed to explore the therapeutic effects and underlying mechanism of exosomes derived from BMSCs treated with CeONPs (BMSC-Ce-exos) in radiation-induced jaw bone injury. Results: In vitro, 25 μg/mL CeONPs were identified as the optimal treatment concentration; BMSC-Ce-exos significantly promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs. In vivo, BMSC-Ce-exos notably promoted bone formation and decreased the ROS levels in rats with radiation-induced jaw bone injury. miRNA sequencing revealed that BMSC-Ce-exos were highly enriched with miR-21-5p, which promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs through targeting STAT3. Conclusions: Collectively, these results suggest that BMSC-Ce-exos provided a potential therapeutic approach for radiation-induced jaw bone injury.

## Linked entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774]
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Mir215 (microRNA 215) [NCBI Gene 100314074] {aka rno-mir-215}, Thy1 (Thy-1 cell surface antigen) [NCBI Gene 24832] {aka CD7}, Mir27b (microRNA 27b) [NCBI Gene 100314005] {aka rno-mir-27b}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, Col1a1 (collagen type I alpha 1 chain) [NCBI Gene 29393] {aka COLIA1}, Cel (carboxyl ester lipase) [NCBI Gene 24254] {aka Bal, Bssl}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, Cd34 (CD34 molecule) [NCBI Gene 305081], Col4a2 (collagen type IV alpha 2 chain) [NCBI Gene 306628], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Ptprc (protein tyrosine phosphatase, receptor type, C) [NCBI Gene 24699] {aka CD45, L-CA, Lca, RT7, T200}, Bglap (bone gamma-carboxyglutamate protein) [NCBI Gene 25295] {aka Bglap2, Bgp, Bgpr, Bgpra}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, Hdac7 (histone deacetylase 7) [NCBI Gene 84582] {aka HD7, HD7a, Hdac7a}, Tsg101 (tumor susceptibility 101) [NCBI Gene 292925] {aka Rw}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Mir34c (microRNA 34c) [NCBI Gene 100314014] {aka rno-mir-34c}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Cd63 (Cd63 molecule) [NCBI Gene 29186], Runx2 (RUNX family transcription factor 2) [NCBI Gene 367218] {aka CBF-alpha-1, Cbfa1, OSF-2}, Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, Bmal1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 29657] {aka Arntl}, Jak2 (Janus kinase 2) [NCBI Gene 24514], Flot2 (flotillin 2) [NCBI Gene 83764], SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, Cd44 (CD44 molecule) [NCBI Gene 25406] {aka CD44A, METAA, RHAMM}, Canx (calnexin) [NCBI Gene 29144], Keap1 (Kelch-like ECH-associated protein 1) [NCBI Gene 117519] {aka Inrf2}, Pecam1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 29583] {aka CD31, Pecam}
- **Diseases:** tumorigenesis (MESH:D063646), hypoxia (MESH:D000860), osteoarthritis (MESH:D010003), CeONPs (MESH:D028361), fractures (MESH:D050723), fibrosis (MESH:D005355), inflammation (MESH:D007249), osteogenic impairment (MESH:D012516), injury to (MESH:D014947), neurodegenerative diseases (MESH:D019636), neuroinflammatory (MESH:D000090862), cancer (MESH:D009369), calcification (MESH:D002114), bone necrosis (MESH:D010020), neurotoxicity (MESH:D020258), depression (MESH:D003866), Jaw Bone Injury (MESH:D007572), cytotoxicity (MESH:D064420), Bone Injury (MESH:D001847), cerebral infarction (MESH:D002544)
- **Chemicals:** IR (MESH:D007495), Napabucasin (MESH:C000621033), Trizol (MESH:C411644), DCF-DA (MESH:C029569), fluorite (MESH:D002124), CeO2 (MESH:C030583), water (MESH:D014867), CCK-8 (MESH:D012844), ceramide (MESH:D002518), Ce (MESH:D002563), ascorbic acid (MESH:D001205), SDS (MESH:D012967), silver (MESH:D012834), Fe3O4 (MESH:C000499), DHE (MESH:C067883), oxygen (MESH:D010100), gold (MESH:D006046), Paraffin (MESH:D010232), platinum (MESH:D010984), metal (MESH:D008670), streptomycin (MESH:D013307), lipid peroxide (MESH:D008054), syringin (MESH:C028305), EDTA (MESH:D004492), nobiletin (MESH:C008661), paraformaldehyde (MESH:C003043), lipid (MESH:D008055), CO2 (MESH:D002245), cetylpyridinium chloride (MESH:D002594), ROS (MESH:D017382), calcium (MESH:D002118), ARS (MESH:C004468), DAPI (MESH:C007293), glucose (MESH:D005947), DAB (MESH:C000469), PVDF (MESH:C024865), PBS (MESH:D007854), sevoflurane (MESH:D000077149), hematoxylin (MESH:D006416), penicillin (MESH:D010406), silica (MESH:D012822), H2O2 (MESH:D006861), superoxide anion (MESH:D013481), DMEM (-), MDA (MESH:D008315), PKH26 (MESH:C070080), beta-glycerophosphate (MESH:C031463), dexamethasone (MESH:D003907)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** BMSC — Oryctolagus cuniculus (Rabbit), Finite cell line (CVCL_B6BB), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), ARPE-19 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0145)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943933/full.md

---
Source: https://tomesphere.com/paper/PMC12943933